The signature was then tested in HM450K data from a larger validation cohort (n = 523) for its ability to predict disease progression (any of BCR, metastases and/or PCa death) and was found to be an independent predictor of progression in multivariate analysis including GS, pathological T-stage and diagnostic PSA level in all patients, and in a subset of GS 7 patients [133]. Here, BCR is linked to posterior cortical atrophy.